AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12867351 — intervention group
Group type: EXPERIMENTAL
Intervention: Illicit drug use
Number of subjects: 190
Study 10980912 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive treatment of dyslipidemia using lovastatin
Number of subjects: 0
Study 9285081 — intervention group
Group type: EXPERIMENTAL
Intervention: Darkness (complete darkness)
Number of subjects: 25
Study 9285081 — intervention group
Group type: COMPARATOR
Intervention: Light (control condition)
Number of subjects: 25
Study 8256106 — intervention group
Group type: EXPERIMENTAL
Intervention: Lariam (mefloquine) 250 mg on alternate weeks
Number of subjects: 105
Study 8256106 — intervention group
Group type: COMPARATOR
Intervention: Fansidar (sulfadoxine and pyrimethamine) one tablet weekly
Number of subjects: 105
Study 8256106 — intervention group
Group type: EXPERIMENTAL
Intervention: Lariam (mefloquine)
Number of subjects: 105
Study 8256106 — intervention group
Group type: EXPERIMENTAL
Intervention: Lariam (mefloquine) metabolite
Number of subjects: 105
Study 8256106 — intervention group
Group type: COMPARATOR
Intervention: Fansidar (sulfadoxine and pyrimethamine)
Number of subjects: 105
Study 3551425 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 57
Study 3551425 — intervention group
Group type: COMPARATOR
Intervention: Gastroplasty
Number of subjects: 57
Study 31898526 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-washing with soap at key times and weekly nail clipping
Number of subjects: 0
Study 31898526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal parasitic infections (IPIs)
Number of subjects: 0
Study 31898526 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemia
Number of subjects: 0
Study 30009729 — intervention group
Group type: EXPERIMENTAL
Intervention: AACD‐CPR
Number of subjects: 69
Study 30009729 — intervention group
Group type: COMPARATOR
Intervention: STD‐CPR
Number of subjects: 69
Study 26701977 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mmol/L Ca (1.25 Ca), n=212
Number of subjects: 425
Study 26701977 — intervention group
Group type: COMPARATOR
Intervention: 1.75 mmol/L Ca (1.75 Ca), n=213
Number of subjects: 425
Study 25683256 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate (3 g/day for 7 days)
Number of subjects: 27
Study 25683256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 24386861 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous androgen deprivation (CAD) therapy
Number of subjects: 93
Study 24386861 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intermittent androgen deprivation (IAD) therapy
Number of subjects: 93
Study 24386861 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified intermittent androgen deprivation (IAD) therapy
Number of subjects: 93
Study 24386861 — intervention group
Group type: COMPARATOR
Intervention: Modified IAD
Number of subjects: 93
Study 24386861 — intervention group
Group type: COMPARATOR
Intervention: Standard IAD
Number of subjects: 93
Study 20358216 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA 300 U
Number of subjects: 120
Study 20358216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 18821290 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (intramuscular injections of testosterone enanthate every three weeks for 12 months)
Number of subjects: 48
Study 18821290 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 48
Study 15669894 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 55
Study 15669894 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 55
Study 12558678 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative neoadjuvant therapy for early stage locally advanced breast cancer
Number of subjects: 0
Study 12558678 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary care
Number of subjects: 0
Study 12558678 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative and coordinated clinical care across disciplines
Number of subjects: 0
Study 12558678 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives for multidisciplinary care
Number of subjects: 0
Study 11090787 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin treatment
Number of subjects: 0
Study 8722606 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol 17‐propionate cream
Number of subjects: 0
Study 8722606 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol 17‐propionate ointment
Number of subjects: 0
Study 8722606 — intervention group
Group type: COMPARATOR
Intervention: 0.1% triamcinolone acetonide cream
Number of subjects: 0
Study 8722606 — intervention group
Group type: COMPARATOR
Intervention: 0.1% triamcinolone acetonide ointment
Number of subjects: 0
Study 8722606 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol 17‐propionate cream and ointment
Number of subjects: 0
Study 1548248 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (approximately 0.005 mg/kg/day)
Number of subjects: 9
Study 1548248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3935780 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course of ampicillin
Number of subjects: 427
Study 3935780 — intervention group
Group type: COMPARATOR
Intervention: Long course of ampicillin
Number of subjects: 427
Study 31572243 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy-enhancing treatment (AET), 15-session group-based
Number of subjects: 83
Study 31572243 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 83
Study 31572243 — intervention group
Group type: EXPERIMENTAL
Intervention: AET
Number of subjects: 83
Study 29873089 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid misuse (defined as use of illicit or prescription opioids without a prescription or not as directed in the previous 6 months)
Number of subjects: 1226
Study 29873089 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid misuse
Number of subjects: 1226
Study 26852717 — intervention group
Group type: EXPERIMENTAL
Intervention: Itch Numeric Rating Scale (Itch NRS)
Number of subjects: 0
Study 24647551 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game training (Lumosity) - 20 sessions of 1 hour each
Number of subjects: 27
Study 24647551 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video game training)
Number of subjects: 27
Study 21864204 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine challenge
Number of subjects: 42
Study 21864204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20393454 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 genotype-based tacrolimus dosing
Number of subjects: 280
Study 20393454 — intervention group
Group type: COMPARATOR
Intervention: Standard daily regimen of tacrolimus
Number of subjects: 280
Study 18592826 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-fine hydrofluoroalkane-beclomethasone (200 microg daily via an Autohaler)
Number of subjects: 33
Study 18592826 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone dry powder inhaler (200 microg daily via a Diskus)
Number of subjects: 33
Study 18592826 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-fine hydrofluoroalkane-beclomethasone
Number of subjects: 33
Study 16117451 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose of 300 IU/kg heparin for total body weight (TBW)
Number of subjects: 27
Study 16117451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose of 300 IU/kg heparin for calculated lean body mass (LBM)
Number of subjects: 27
Study 12297361 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin-clavulanate 2000/125 mg, twice daily
Number of subjects: 344
Study 12297361 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin-clavulanate 1000/125 mg, three times daily
Number of subjects: 344
Study 12297361 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 344
Study 10726961 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg bolus infusion)
Number of subjects: 16
Study 9166360 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin administration to stimulate the pregnant uterus or ripen the cervix
Number of subjects: 0
Study 9166360 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin receptor antagonists
Number of subjects: 0
Study 8445237 — intervention group
Group type: EXPERIMENTAL
Intervention: Malotilate (500 mg three times a day)
Number of subjects: 101
Study 8445237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 8445237 — intervention group
Group type: EXPERIMENTAL
Intervention: Malotilate
Number of subjects: 101
Study 3088739 — intervention group
Group type: EXPERIMENTAL
Intervention: hydroflumethiazide 50 mg, Rauwolfia serpentina 50 mg and potassium chloride 625 mg (HFRK)
Number of subjects: 14
Study 3088739 — intervention group
Group type: EXPERIMENTAL
Intervention: clopamide 5 mg, reserpine 0.1 mg and dihydroergocristine 0.5 mg (CRE)
Number of subjects: 14
Study 3088739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 29752028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO-OP) Approach
Number of subjects: 30
Study 26894929 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone treatment
Number of subjects: 114
Study 24890996 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior stabilized (PS) polyethylene with a post
Number of subjects: 25
Study 24890996 — intervention group
Group type: COMPARATOR
Intervention: Cruciate substituting (CS) polyethylene without a post
Number of subjects: 25
Study 24890996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball and socket joint
Number of subjects: 25
Study 22682705 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 15
Study 22682705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 20194698 — intervention group
Group type: EXPERIMENTAL
Intervention: SP+AS+PQ (0.75 mg/kg of body weight)
Number of subjects: 441
Study 20194698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 20194698 — intervention group
Group type: COMPARATOR
Intervention: SP+AS
Number of subjects: 441
Study 20194698 — intervention group
Group type: EXPERIMENTAL
Intervention: G6PD A-
Number of subjects: 441
Study 20194698 — intervention group
Group type: EXPERIMENTAL
Intervention: G6PD A
Number of subjects: 441
Study 20194698 — intervention group
Group type: EXPERIMENTAL
Intervention: G6PD B
Number of subjects: 441
Study 18602045 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric gasless laparoscopic‐assisted minilaparotomy (LA‐MLT)
Number of subjects: 52
Study 18602045 — intervention group
Group type: COMPARATOR
Intervention: Isobaric gasless laparoscopic (LA)
Number of subjects: 52
Study 18602045 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 52
Study 18602045 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 16204902 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate anti-H. pylori treatment and oral ferrous sulfate
Number of subjects: 52
Study 16204902 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed anti-H. pylori treatment and oral ferrous sulfate
Number of subjects: 52
Study 16204902 — intervention group
Group type: EXPERIMENTAL
Intervention: Only oral ferrous sulfate (H. pylori negative patients)
Number of subjects: 52
Study 16204902 — intervention group
Group type: COMPARATOR
Intervention: Delayed anti-H. pylori treatment after one month
Number of subjects: 52
Study 12432836 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine injection (1:10,000)
Number of subjects: 500
Study 12432836 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine plus 2% polidocanol
Number of subjects: 500
Study 12432836 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine injection
Number of subjects: 500
Study 12432836 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine plus sclerosing agent
Number of subjects: 500
Study 10489947 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin alone (n=233)
Number of subjects: 693
Study 10489947 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin plus rifabutin (n=224)
Number of subjects: 693
Study 10489947 — intervention group
Group type: COMPARATOR
Intervention: Rifabutin alone (n=236)
Number of subjects: 693
Study 8564089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 5 mg/kg/d for 36 weeks
Number of subjects: 39
Study 8564089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 8564089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 39
Study 1827014 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine after 4 weeks
Number of subjects: 17
Study 1827014 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine after 12 weeks
Number of subjects: 17
Study 1827014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 30350117 — intervention group
Group type: EXPERIMENTAL
Intervention: Heating pad applied to the patient's sacrum during cystoscopy
Number of subjects: 74
Study 30350117 — intervention group
Group type: COMPARATOR
Intervention: Control group using a pad without heat
Number of subjects: 74
Study 30814177 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary debulking surgery
Number of subjects: 303
Study 30814177 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy
Number of subjects: 303
Study 30814177 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary debulking surgery with no residual disease
Number of subjects: 303
Study 30814177 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary debulking surgery with any residual disease
Number of subjects: 303
Study 30814177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy
Number of subjects: 303
Study 30814177 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy
Number of subjects: 303
Study 26340744 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib (150 mg dabrafenib twice daily combined with 2 mg trametinib once daily)
Number of subjects: 54
Study 26340744 — intervention group
Group type: COMPARATOR
Intervention: Dabrafenib alone
Number of subjects: 54
Study 26340744 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib (after adjustment for treatment switching)
Number of subjects: 54
Study 26340744 — intervention group
Group type: COMPARATOR
Intervention: Dabrafenib alone (before adjustment for treatment switching)
Number of subjects: 54
Study 23579334 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive rehabilitation
Number of subjects: 36
Study 23579334 — intervention group
Group type: COMPARATOR
Intervention: Nonaggressive rehabilitation
Number of subjects: 36
Study 21404197 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily
Number of subjects: 117
Study 21404197 — intervention group
Group type: COMPARATOR
Intervention: Control group (hydration and analgesic on demand)
Number of subjects: 117
Study 19564251 — intervention group
Group type: EXPERIMENTAL
Intervention: Materials Group (mailed educational materials)
Number of subjects: 46
Study 19564251 — intervention group
Group type: EXPERIMENTAL
Intervention: Materials plus Personal Encounters Group (educational materials through interactions with community health workers)
Number of subjects: 46
Study 19564251 — intervention group
Group type: EXPERIMENTAL
Intervention: All children (combined data from both intervention groups)
Number of subjects: 46
Study 19564251 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized contemporaneous control group
Number of subjects: 46
Study 18245999 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Marcain (96 mL, 2 mL/h for 48 hours)
Number of subjects: 26
Study 18245999 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 26
Study 18245999 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Marcain
Number of subjects: 26
Study 14985887 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-gadolinium T1-weighted images with magnetization transfer (MT)
Number of subjects: 31
Study 14985887 — intervention group
Group type: COMPARATOR
Intervention: Post-gadolinium T1-weighted images without magnetization transfer (MT)
Number of subjects: 31
Study 14985887 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtraction images without magnetization transfer (MT)
Number of subjects: 31
Study 11737399 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV + ddI
Number of subjects: 3207
Study 11737399 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV + ddC
Number of subjects: 3207
Study 11737399 — intervention group
Group type: COMPARATOR
Intervention: ZDV
Number of subjects: 3207
Study 9605669 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine (GLN) 0.5 g/kg/day during MTX neoadjuvant therapy
Number of subjects: 9
Study 9605669 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) 40 mg/m2 to 100 mg/m2 weekly for 3 weeks
Number of subjects: 9
Study 8273984 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of omeprazole daily
Number of subjects: 10
Study 8273984 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of omeprazole daily
Number of subjects: 10
Study 2658396 — intervention group
Group type: EXPERIMENTAL
Intervention: telenzepine 3 mg once-daily at bedtime
Number of subjects: 314
Study 2658396 — intervention group
Group type: COMPARATOR
Intervention: pirenzepine 50 mg two times daily
Number of subjects: 314
Study 1124593 — intervention group
Group type: EXPERIMENTAL
Intervention: Commode use during defecation
Number of subjects: 51
Study 1124593 — intervention group
Group type: COMPARATOR
Intervention: Bedpan use during defecation
Number of subjects: 51
Study 31678098 — intervention group
Group type: EXPERIMENTAL
Intervention: LOR-mod (moderate-dose Lorexys)
Number of subjects: 0
Study 31678098 — intervention group
Group type: COMPARATOR
Intervention: BUP (standard dose bupropion)
Number of subjects: 0
Study 31678098 — intervention group
Group type: EXPERIMENTAL
Intervention: LOR-low (subtherapeutic dose Lorexys)
Number of subjects: 0
Study 27646264 — intervention group
Group type: EXPERIMENTAL
Intervention: High saturated fat meal
Number of subjects: 58
Study 27646264 — intervention group
Group type: COMPARATOR
Intervention: High oleic sunflower oil meal
Number of subjects: 58
Study 27646264 — intervention group
Group type: EXPERIMENTAL
Intervention: History of major depressive disorder (MDD)
Number of subjects: 58
Study 25264599 — intervention group
Group type: EXPERIMENTAL
Intervention: Handling Our Problems Effectively (HOPE)
Number of subjects: 145
Study 25264599 — intervention group
Group type: EXPERIMENTAL
Intervention: Forgiveness and Reconciliation through Experiencing Empathy (FREE)
Number of subjects: 145
Study 25264599 — intervention group
Group type: COMPARATOR
Intervention: Repeated assessment controls
Number of subjects: 145
Study 22914115 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic airway devices (SAD)
Number of subjects: 50
Study 22914115 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation (ETI)
Number of subjects: 50
Study 22914115 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth-to-mouth ventilation
Number of subjects: 50
Study 20965577 — intervention group
Group type: EXPERIMENTAL
Intervention: RTL1000 (≤60 mg)
Number of subjects: 34
Study 20965577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 18317424 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study 18317424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with physician extender visit
Number of subjects: 140
Study 17057563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT)
Number of subjects: 123
Study 17057563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 13680036 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA 0.3 mg/kg iv
Number of subjects: 6
Study 13680036 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA 1 mg/kg iv
Number of subjects: 6
Study 13680036 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA 3 mg/kg iv
Number of subjects: 6
Study 13680036 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA 6 mg/kg iv
Number of subjects: 6
Study 13680036 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 6
Study 10900778 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with Support (school-based anti-bullying intervention with additional support)
Number of subjects: 1104
Study 10900778 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment without Support (school-based anti-bullying programme without additional support)
Number of subjects: 1104
Study 10900778 — intervention group
Group type: COMPARATOR
Intervention: Control (schools that did not implement the anti-bullying programme)
Number of subjects: 1104
Study 8737127 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 1137
Study 8737127 — intervention group
Group type: COMPARATOR
Intervention: Comparator antibacterial agents (amoxycillin/clavulanic acid, erythromycin, or amoxycillin)
Number of subjects: 1137
Study 1570234 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Troleandomycin (TAO) therapy
Number of subjects: 11
Study 4047798 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 25% of total calories as fat
Number of subjects: 18
Study 4047798 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 50% of total calories as fat
Number of subjects: 18
Study 4047798 — intervention group
Group type: EXPERIMENTAL
Intervention: Preliminary observation period
Number of subjects: 18
Study 4047798 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat intake (less than 27% of total calories)
Number of subjects: 18
Study 29705444 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand and foot surface stroke massage
Number of subjects: 70
Study 29705444 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study 27091601 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanol-rich dark chocolate (50g)
Number of subjects: 65
Study 27091601 — intervention group
Group type: COMPARATOR
Intervention: Placebo chocolate (50g)
Number of subjects: 65